This HTML5 document contains 194 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n11http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n13https://scigraph.springernature.com/pub.10.1007/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q38677229
rdf:type
wikibase:Item
schema:description
wissenschaftlicher Artikel vitskapeleg artikkel 2017年论文 artigo científico 2017年論文 2017年论文 научная статья 2017年论文 artikulong pang-agham научни чланак scientific article published on 15 July 2017 2017 nî lūn-bûn bài báo khoa học 2017年论文 videnskabelig artikel บทความทางวิทยาศาสตร์ artykuł naukowy научни чланак სამეცნიერო სტატია scientific article published on 15 July 2017 vědecký článek wetenschappelijk artikel наукова стаття, опублікована в липні 2017 2017年論文 2017年论文 vedecký článok מאמר מדעי επιστημονικό άρθρο artikel ilmiah scienca artikolo مقالة علمية نشرت في 15 يوليو 2017 articol științific artigo científico 2017年論文 2017년 논문 বৈজ্ঞানিক নিবন্ধ scientific article published on 15 July 2017 article scientific naučni članak 2017年の論文 article científic научна статия 2017年論文 artikull shkencor bilimsel makale artículo científico мақолаи илмӣ artículu científicu espublizáu en 2017 article scientifique vetenskaplig artikel vitenskapelig artikkel 2017年论文 artigo científico 2017年論文 teaduslik artikkel articolo scientifico tudományos cikk tieteellinen artikkeli
p:P577
wds:Q38677229-220F30DB-7DB0-428F-8994-D4743FB3A68F
wdt:P577
2017-07-15T00:00:00Z
p:P2888
wds:Q38677229-1D767ECD-F8D2-4356-8F28-D31B2C7B0D84
wdt:P2888
n13:s40618-017-0729-4
p:P2860
wds:Q38677229-C5C6FFD2-929D-45E3-908C-4568E198461E wds:Q38677229-C7A6D754-0C32-4FB5-BABF-B214F6875BF7 wds:Q38677229-BECAE631-B230-4F02-9DE5-12C10ABC50A1 wds:Q38677229-BEE9CAF1-30BE-45F9-A2DD-BA01227C054A wds:Q38677229-C07B7270-B016-40A9-816E-A798C0C611AE wds:Q38677229-75A3819A-E140-4993-89B3-2A9A0DB15A00 wds:Q38677229-77C1385C-4FD8-4639-9F56-F9E0D3B1E191 wds:Q38677229-785B5D18-D0A9-4BAD-A85D-507CD19BDE2B wds:Q38677229-7F012E29-4F70-44B2-A9D9-422A109D91E0 wds:Q38677229-66910920-F5B5-4A5F-9962-E26BC0E21D5D wds:Q38677229-6B1E7AC8-6A3B-4575-9E4C-857E85E5529F wds:Q38677229-7387372E-A560-4586-A847-334AE9859F73 wds:Q38677229-8E115640-FFAA-4AEA-B256-088B9027D39B wds:Q38677229-8E8D0FB2-DFDD-4EE4-A6E7-79638AF5EE18 wds:Q38677229-932990E7-108D-49B1-B8DC-AA3F3FF406B4 wds:Q38677229-8648C432-8B75-4F28-93D2-301DBD12F456 wds:Q38677229-875B09F4-78FC-46C8-B15E-9C30B4B3FBD3 wds:Q38677229-88525828-09AF-43CB-8307-297239A426EC wds:Q38677229-16DF2B1A-88AB-46C4-881D-3FADEF464905 wds:Q38677229-1AC30074-DF86-4700-9015-4FA67EBBB8F3 wds:Q38677229-036E9132-878B-4803-B5FE-E714A7607877 wds:Q38677229-0ACC075D-5917-4F93-BAF2-12111E9B6AC9 wds:Q38677229-5D58574E-12BF-47C3-A77F-D49F4F850E84 wds:Q38677229-20ABC672-D645-427C-A547-BAD2085BD74D wds:Q38677229-2310F642-6E4B-45BC-9F7A-D976056CDD0B wds:Q38677229-23CE918D-B0C3-4D83-AE7F-80825CB182C6 wds:Q38677229-D87995C7-BE90-42B7-AADD-55C950C630CC wds:Q38677229-DDC1BA8E-FB59-49C9-849B-9F44D8080202 wds:Q38677229-DE8CD9C3-92CA-4737-B374-20BED0EDC705 wds:Q38677229-D147A500-D3AC-4547-B1D5-1628E32D5F80 wds:Q38677229-D26D2322-04E7-443C-879B-F73469A17564 wds:Q38677229-D471A317-1FDB-4F32-8DF0-5FBAA874E3D4 wds:Q38677229-D4BADACB-9A41-496C-8EF8-1BA1CD5F665D wds:Q38677229-F4B6285F-E0BE-4EB2-BBF5-D9D817F61137 wds:Q38677229-DF66CD3C-7731-4236-8C43-3EBE09434892 wds:Q38677229-E318A8D1-4BDB-4332-9AB6-052B6A80EF0C wds:Q38677229-B46E57C5-407E-41E7-8D25-AD243AEA9ABF wds:Q38677229-BAB49D5D-4402-46A4-B472-C2DAFF5384EA wds:Q38677229-BC6954AE-EF57-45E8-A63A-40AB584F2F6E
wdt:P2860
wd:Q38666884 wd:Q38678441 wd:Q38891353 wd:Q38594595 wd:Q56068835 wd:Q44522211 wd:Q57740599 wd:Q38371024 wd:Q34070335 wd:Q44513183 wd:Q58645594 wd:Q41583378 wd:Q43958971 wd:Q38202745 wd:Q37982966 wd:Q39497957 wd:Q29614889 wd:Q40463524 wd:Q80443663 wd:Q81535977 wd:Q86939556 wd:Q79689991 wd:Q28087002 wd:Q42477084 wd:Q36113099 wd:Q38956283 wd:Q30336517 wd:Q51250548 wd:Q35223184 wd:Q83884558 wd:Q37662291 wd:Q38333088 wd:Q38834737 wd:Q45114719 wd:Q51325471 wd:Q44922629 wd:Q39339098 wd:Q87419203 wd:Q44722477
p:P2093
wds:Q38677229-68501AF5-9CAD-4035-A015-E8124AAE6CC9 wds:Q38677229-A687649B-21FD-480A-AACC-7183E75AB3ED wds:Q38677229-B336F959-1CB1-459B-B3D6-10FBF1C7BE95 wds:Q38677229-C681610F-7703-4601-8B39-21E71FFE7769 wds:Q38677229-FC0C993A-5C0E-46FF-84F8-8645C67E029D wds:Q38677229-11E772A3-5539-4831-B6E8-4AC9EBF4EF65 wds:Q38677229-641A4619-680F-4955-9D6F-2D9000C6332A wds:Q38677229-2FC2EA99-E78D-4B54-8434-63CDC489B555
wdt:P2093
G Zoppini G Morani C Dugo E Bonora B Bolzan R Rigolon G Targher A Civettini
rdfs:label
Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring
skos:prefLabel
Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring
schema:name
Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring
p:P50
wds:Q38677229-C155A1F4-411D-46DA-90C4-A6EE5354C790 wds:Q38677229-B34C0834-A498-4523-A5DF-867E4DBD28D7
wdt:P50
wd:Q38800256 wd:Q59682931
p:P1476
wds:Q38677229-F09EE336-663B-4B79-8D3B-D380E19B2E72
wdt:P1476
Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring
p:P304
wds:Q38677229-667CC7C0-050D-4844-8E4B-DC16AEF1B18C
wdt:P304
223-231
p:P31
wds:Q38677229-BA2B8D1B-4E96-481A-AB8B-640CC3F59867
wdt:P31
wd:Q13442814
p:P921
wds:Q38677229-AFD05798-B65A-4784-B59D-FC01D5BB6339 wds:Q38677229-0EC0992B-4363-4ED5-A7FD-D62FABF4A00F
wdt:P921
wd:Q3025883 wd:Q815819
p:P698
wds:Q38677229-824B1D2F-82DA-4B3D-AB68-DFBB41F6D61D
wdtn:P698
n8:28711969
wdt:P698
28711969
p:P1433
wds:Q38677229-CB5C40A3-FC80-4B6D-A592-F647887B4422
wdt:P1433
wd:Q15766847
p:P433
wds:Q38677229-A7A239A1-A0FC-4B2A-BA7D-5E201D02EEE9
p:P478
wds:Q38677229-E4F21CD1-4C3C-4DC7-AD2A-2B3C2678DC1B
wdt:P433
2
wdt:P478
41
p:P356
wds:Q38677229-1BB0B103-C19C-4A5F-967B-D5EB7A9A8AA7
wdtn:P356
n11:S40618-017-0729-4
wdt:P356
10.1007/S40618-017-0729-4
p:P6179
wds:Q38677229-DA2D6A62-D87E-4550-9783-C3E9EFFF4371
wdt:P6179
1090684763